Evidence map›Paper›PMID 40856428›Full record

Observational studyCancer medicine2025

Electronic Patient-Reported Outcome Quality of Life Score in Japanese Patients With Pancreatic Cancer on Second-Line Chemotherapy: A Multicenter Observational Study.

Yuki Takumoto, Akihiro Ohba, Takeshi Terashima, Makoto Ueno, Kenji Ikezawa, Naohiro Okano, Takuji Okusaka, Chigusa Morizane, Masafumi Ikeda, Masato Ozaka and 4 more

Abstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yuki TakumotoCenter for Outcomes Research and Economic Evaluation for Health, National Institute of Public Health, Saitama, Japan.ORCID https://orcid.org/0000-0001-9191-3494
Akihiro OhbaDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Takeshi TerashimaDepartment of Gastroenterology, Kanazawa University Hospital, Kanazawa, Japan.
Makoto UenoDepartment of Gastroenterology, Kanagawa Cancer Center, Kanagawa, Japan.ORCID https://orcid.org/0000-0003-4480-0029
Kenji IkezawaDepartment of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka, Japan.ORCID https://orcid.org/0000-0001-7517-8960
Naohiro OkanoDepartment of Medical Oncology, Kyorin University Faculty of Medicine, Tokyo, Japan.ORCID https://orcid.org/0000-0002-4098-5217
Takuji OkusakaDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Chigusa MorizaneDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Masafumi IkedaDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Masato OzakaGastroenterology Center, Gastroenterological Medicine, The Cancer Institute Hospital of JFCR, Tokyo, Japan.
Hiroto NarimatsuCancer Prevention and Control Division, Kanagawa Cancer Center Research Institute, Kanagawa, Japan.ORCID https://orcid.org/0000-0002-5302-5872
Manabu AkazawaDepartment of Public Health and Epidemiology, Meiji Pharmaceutical University, Tokyo, Japan.
Takeru ShiroiwaCenter for Outcomes Research and Economic Evaluation for Health, National Institute of Public Health, Saitama, Japan.
Junji FuruseDepartment of Gastroenterology, Kanagawa Cancer Center, Kanagawa, Japan.

Funding

Public Health Research Foundation
6 · The paper itself

Abstract

introductionPatients' QoL scores during chemotherapy are generally measured during hospital visits. However, patients frequently recover from AEs before hospital arrival. This study continuously assessed each chemotherapy's impact on patients' QoL scores during hospital visits and at home using an electronic device (ePRO).

methodsThis multicenter, prospective observational study was conducted in 29 Japanese hospitals. Patients were treated with liposomal irinotecan, fluorouracil, and levoleucovorin (Nal-IRI + 5-FU/LV), gemcitabine and nab-paclitaxel (GnP), or gemcitabine (GEM) as second-line chemotherapy for unresectable pancreatic cancer. All respondents used ePRO to answer several QoL questionnaires on Days 1, 2, 4, 6, 8, and 11 following chemotherapy administration. The primary endpoint was the EQ-5D-5L index value, and the secondary endpoints were AE frequency and the EORTC QLQ-C30.

resultsThe analysis included 67 participants. The mean ± SD QoL scores of the Nal-IRI + 5-FU/LV and GnP arms varied from 0.803 ± 0.142 to 0.678 ± 0.247 and 0.872 ± 0.077 to 0.726 ± 0.185, respectively, over the evaluation period. The highest and lowest QoL scores were observed around the chemotherapy administration and approximately 1 week after the chemotherapy administration, respectively, in both arms.

conclusionsPatients' QoL score assessment over time by ePRO revealed QoL score trends, which emphasized the importance of QoL management outside of hospital visits for each chemotherapy.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsPancreatic NeoplasmsPatient Reported Outcome MeasuresQuality of LifeAdultAgedAged, 80 and overAlbuminsDeoxycytidineEast Asian PeopleFemaleFluorouracilGemcitabineHumansIrinotecanJapan130-nm albumin-bound paclitaxelAlbuminsDeoxycytidineFluorouracilGemcitabineIrinotecanPaclitaxelchemotherapyelectronic patient‐reported outcomeEORTC‐QLQ‐C30EQ‐5D‐5Lhealth‐related quality of lifepancreatic cancerPRO‐CTCAE

Identifiers

PMID40856428
PMCPMC12378663

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.